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Abstract
Induced pluripotent stem cells (iPSCs) are adult somatic cells genetically repro‐
grammed to an embryonic stem cell‐like state. Notwithstanding their autologous 
origin and their potential to differentiate towards cells of all three germ layers, iPSC 
reprogramming is still affected by low efficiency. As dermal fibroblast is the most 
used human cell for reprogramming, we hypothesize that the variability in repro‐
gramming is, at least partially, because of the skin fibroblasts used. Human dermal 
fibroblasts harvested from five different anatomical sites (neck, breast, arm, abdo‐
men and thigh) were cultured and their morphology, proliferation, apoptotic rate, 
ability to migrate, expression of mesenchymal or epithelial markers, differentiation 
potential and production of growth factors were evaluated in vitro. Additionally, 
gene expression analysis was performed by real‐time PCR including genes typically 
expressed by mesenchymal cells. Finally, fibroblasts isolated from different ana‐
tomic sites were reprogrammed to iPSCs by integration‐free method. Intriguingly, 
while the morphology of fibroblasts derived from different anatomic sites differed 
only slightly, other features, known to affect cell reprogramming, varied greatly and 
in accordance with anatomic site of origin. Accordingly, difference also emerged in 
fibroblasts readiness to respond to reprogramming and ability to form colonies. 
Therefore, as fibroblasts derived from different anatomic sites preserve positional 
memory, it is of great importance to accurately evaluate and select dermal fibroblast 
population prior to induce reprogramming.
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1  | INTRODUC TION
Induced pluripotent stem cells (iPSCs) are adult somatic cells ge‐
netically reprogrammed to an embryonic stem cell (ESC)‐like state. 
Since pioneering works that led to the successful reprogramming of 
mouse1 and human2,3 fibroblasts, iPSCs have been obtained from 
somatic cells of several other species.4‐6
Remarkable similarity of iPSCs to ESC, along with their origin 
from adult somatic cells, make iPSCs a tremendously valuable tool 
for regenerative medicine, disease modelling, drug discovery and 
testing,7‐9 while avoiding the ethical concerns associated with ESC.
Notwithstanding iPSCs functional resemblance to ESC, their 
clinical application is still prevented by severe technical prob‐
lems, mostly related to both reprogramming technology and low 
efficiency of reprogramming. Although reprogramming technol‐
ogy has been significantly improved by integration‐free methods 
based on episomal vectors,10 synthetic modified mRNA11 or di‐
rect delivery of reprogramming proteins,12 efficiency of repro‐
gramming of human cells is still as low as 2% with integration‐free 
methods, and 6.2% at best with integration methods.13 Several en‐
hancers and barriers of reprogramming have been described thus 
far. Accordingly, novel strategies to activate enhancers or inhibit 
barriers are emerging.14 Recently, reprogramming efficiencies of 
80%‐100% were achieved by genetic combinatorial modulation 
of specific signalling pathways.15 These results shed light on the 
mechanisms governing cell reprogramming, but do not allow tran‐
scending the limitations to iPSC clinical translation. Additionally, 
evidence supporting variability in efficiency of reprogramming and 
in properties of iPSCs in accordance with the cell type from which 
iPSCs were generated was also reported.16,17 Adult dermal fibro‐
blast has been the first human cell successfully reprogrammed to 
iPSCs,3 and, to date, it is still the most used human cell for re‐
programming. Even though the potential of other adult somatic 
cells has been examined, fibroblasts are still the most suitable cell 
source to generate iPSC. Intriguingly, peripheral blood cells (PBCs) 
and urine‐derived cells (HUCs) were emerging as alternate can‐
didates for easiness of harvesting, but the very low efficiency of 
PBCs reprogramming and the very high inter‐individual variation 
in HUCs number excreted with urine,13 strengthened fibroblast 
role in human iPSCs production. Undoubtedly, dermal fibroblasts 
are easily accessible and propagated in culture with a single skin 
punch biopsy. However, according to gene expression profile 
analysis independently performed by different groups comparing 
fibroblasts from different anatomic sites, embryonic spatial or‐
ganisation of fibroblast differentiation and positional memory are 
partially retained in adult fibroblast.18,19 Furthermore, recently re‐
ported phenotypic and functional diversity of dermal fibroblasts20 
might need to be considered when planning reprogramming of 
dermal fibroblasts to iPSCs.
On this basis, we hypothesize that dermal fibroblasts differ not 
only in their gene expression profile, but also in other biological 
characteristics that might be, even partially, responsible for different 
response to reprogramming technology. To test our hypothesis we 
compared the morphology, expression of specific markers, produc‐
tion of soluble factors, proneness to apoptosis, proliferation rate, 
ability to migrate and differentiation potential of adult human der‐
mal fibroblasts isolated from different anatomic sites and analysed 
any difference occurring among cell populations.
2  | MATERIAL S AND METHODS
2.1 | Tissue samples
Skin fragments from five different anatomic sites (n = 25, five necks, 
five breasts, five arms, five abdomens and five thighs) of patients 
(n = 25, mean age 41.04 ± 7.624, all female patients) undergoing plastic 
surgery were harvested. Patients provided written, informed consent 
and specimens were collected, without patient identifiers, following 
protocols approved by the University Hospital Federico II and in con‐
formity with the principles outlined in the Declaration of Helsinki.
2.2 | Cell culture
Samples were minced and fragments of about 2 × 1 mm, length 
by width, were placed under sterile coverglasses in 35 mm culture 
plates and cultured in DMEM (Sigma‐Aldrich, St. Louis, MO) with 
10% FBS (Fetal Bovine Serum) (Sigma‐Aldrich) and 0.5% Penicillin‐
Streptomycin (Sigma‐Aldrich), at 37°C in 5% CO2. Plates were 
checked daily at an inverted phase‐contrast microscope (Olympus, 
Tokyo, Japan), and medium was replaced every 3 days. Outgrowth 
of cells was documented by digital image acquisition (Olympus). 
Confluent fibroblasts from all regions were synchronised by being 
placed in 0.1% serum for 48 hours before being trypsinized and 
plated in the presence of 10% serum, as previously described.21 In 
order to avoid any effect because of the native environment, all pri‐
mary fibroblasts were cultured under the same condition in vitro for 
five passages.18 Then, passage 5 fibroblasts from different anatomic 
sites were cultured for 1 week to evaluate their features and behav‐
iour in vitro. All experiments were performed in triplicate.
2.3 | Scratch wound assay
1.6 × 105 cells/35 mm dish were plated to create a confluent mon‐
olayer. Dishes were cultured for approximately 48 hours at 37°C 
to allow cells to adhere and spread. Cell monolayer was scratched 
in a straight line with a p10 sterile pipette tip. Fresh medium was 
pipetted in the dish, after one wash with medium to remove de‐
bris. Culture plates were then placed under a phase‐contrast mi‐
croscope (Nikon, Tokyo, Japan) equipped with stage incubator 
(Okolab, Pozzuoli, Italy), and the migration of fibroblasts at both 
edges of the wound was documented acquiring one picture every 
10 minutes for 12 hours by digital camera (Nikon). Data were ana‐
lysed by NIS Elements software (Nikon) and expressed as mean 
speed of migration ± SE.
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2.4 | Immunocytochemistry and proliferation index
7.5 × 104 cells/35 mm dish were plated and cultured for 4 days in 
DMEM with 10% FBS. Cells were then fixed in 4% paraformalde‐
hyde and immunostained. After three brief washes in PBS, cells were 
blocked with 10% donkey serum (Sigma‐Aldrich), then incubated for 
1 hour at 37°C in humidified chamber with primary antibodies tar‐
geting vimentin, cadherin, smooth muscle actin, Factor VIII (all from 
Sigma‐Aldrich), CD90, (Cluster of Differentiation 90) CD105 (both 
from Abcam, Cambridge, UK) or Ki67 (Leica Biosystems, Wetzlar, 
Germany). After washing, cells were incubated with matching sec‐
ondary antibody (Jackson ImmunoResearch, Newmarket, UK) either 
fluorescein or rhodamine‐conjugated. After a further wash, stained 
area of culture dish was mounted with coverglasses in Vectashield 
mounting medium with DAPI (4',6‐Diamidino‐2‐Phenylindole) 
(Vector Laboratories, Burlingame, CA). Observation, evaluation 
and documentation were performed by fluorescence microscope 
(Nikon). For ki67 staining, three independent observers counted 
all cells counterstained with DAPI and all ki67‐positive cells in the 
stained area. Results were averaged and proliferation index was cal‐
culated and expressed as mean percentage of cycling cells ± SE.
2.5 | Apoptotic index
To determine apoptotic index of fibroblast from all regions, 
7.5 × 104 cells/35 mm culture dish were plated and cultured for 
3 days, then fixed in 1% paraformaldehyde. Apoptotic cells were 
detected in situ by the indirect TUNEL (Terminal deoxynucleoti‐
dyl transferase dUTP nick end labeling) method using the ApopTag 
Fluorescein In Situ Apoptosis Detection Kit (Merck Millipore, 
Darmstadt, Germany), following supplied protocol. Then, three in‐
dependent observers counted all cells counterstained with DAPI 
and all apoptotic cells in the stained area, under a fluorescence 
microscope (Nikon). Numbers were averaged and apoptotic index 
was calculated and expressed as mean percentage of apoptotic 
cells ± SE.
2.6 | Gene expression profile analysis
Culture dishes(5 × 105 cells/60 mm) were plated and cultured for 
7 days, then processed for real‐time PCR analysis as previously 
described.22 Total RNA was extracted in Isol‐RNA Lysis Reagent 
(5Prime, Hamburg, Germany), dissolved in RNase‐free water and 
its final concentration determined at the NanoDrop 1000 spec‐
trophotometer (Thermo Scientific, Waltham, MA). RNA from each 
sample was reverse transcribed into cDNA with QuantiTect Reverse 
Trascription Kit (Qiagen, Hilden, Germany) and gene expression was 
quantified by real‐time qPCR using PrecisionPLUS qPCR Master 
Mix (Primer Design, Southampton, UK). The primer assays for genes 
typical for mesenchymal cells are included in Table 1. All samples 
were tested in triplicate with the housekeeping gene (GAPDH, 
Glyceraldehyde‐3‐Phosphate Dehydrogenase) to correct for varia‐
tions in RNA quality and quantity. Melt curve analysis was performed 
to assess uniformity of product formation, primer dimer formation 
and amplification of non‐specific products. Comparative quantifica‐
tion of target genes expression in the samples was performed based 
on cycle threshold (Ct) and using the ΔΔCt method. Numbers were 
averaged and expressed as mean ± SE.
2.7 | Growth factor array
Dermal fibroblasts from all five regions (neck, breast, arm, abdomen 
and thigh) were plated at medium density (8 × 104 cells/35 mm) and 
cultured in DMEM with 10% FBS. When cells reached confluence, 
serum‐free FibroGRO medium (Millipore, Burlington, MA) was used 
instead of DMEM for the next 3 days. Culture medium was then col‐
lected from fibroblasts of all dermal regions and assayed in the Human 
Growth Factor Array C1 (Raybiotech, Norcross, GA) to simultane‐
ously detect 41 targets. The procedure was performed in strict ac‐
cordance with manufacturer's directions. Briefly, array membranes 
were blocked with blocking buffer for 30 minutes at room tempera‐
ture, and then 1 mL of culture medium was added to each membrane 
and incubated at room temperature for 2.5 hours. Membranes were 
then washed three times in wash buffer I and twice in wash buffer 
II, then incubated with biotin‐conjugated antibody overnight at 4°C. 
After further washes, membranes were incubated for 2 hours at 
room temperature with horseradish peroxidase (HRP)‐conjugated 
streptavidin and washed one last time to remove unbound reagents. 
All incubation steps were performed with agitation on orbital shaker. 
Membranes were then developed with the detection buffer, exposed 
to film and processed by autoradiography. Numerical comparison of 
the signal densities of growth factors known to influence or modulate 
TA B L E  1   Primers of genes analysed by real‐time PCR
Gene symbol Forward sequence Reverse sequence
Amplicon 
length (nt)
GAPDH 5′‐CTCTCTGCTCCTCCTGTTCG‐3′ 5′‐ACGACCAAATCCGTTGACTC‐3′ 114
CD90 5′‐CTAGTGGACCAGAGCCTTCG‐3′ 5′‐GCCCTCACACTTGACCAGTT‐3′ 96
CD105 5′‐CCTCTACCTCAGCCCACACT‐3′ 5′‐CTGTCTAACTGGAGCAGGAACTC‐3′ 92
CD146 5′‐AGCCAAACATCCAGGTCAAC‐3′ 5′‐TACCCGTTCCTCCCTACACA‐3′ 88
ECM2 5′‐ATCCTTTTCAAGTTTTCCTGGAG‐3′ 5′‐TGCCCTTTACCAAACAGTGTC‐3′ 80
FN1 5′‐ACCGAGGTGACTGAGACCAC‐3′ 5′‐GACACAACGATGCTTCCTGA‐3′ 137
WISP1 5′‐TGGCAGCAGTGACAGCA‐3′ 5′‐GGAGCTGGGGTAAAGTCCAT‐3′ 88
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reprogramming was performed as previously described.23 Briefly, spot 
signal densities from the scanned images of arrays were obtained 
using ImageJ densitometry software (https://imagej.nih.gov/ij/down‐
load.html). The background was then subtracted from the densitom‐
etry data, and the obtained values were normalised to the positive 
control signals. Data were expressed as the mean ± SE.
2.8 | Differentiation potential
Passage 5 fibroblasts were seeded onto 35 mm standard plastic cul‐
ture dishes (BD Falcon) in adipogenic, chondrogenic and osteogenic 
induction media as previously described.24 Dishes were checked 
daily at an inverted phase‐contrast microscope (Olympus) and mor‐
phological changes occurring were documented. The culture me‐
dium was replaced every 3 days and fibroblasts were kept in culture 
for 21 days. Then, cells were rinsed in PBS and fixed for 20 minutes 
in 4% neutral buffered paraformaldehyde. Differentiation was con‐
firmed by histological staining using specific staining kits (Bio‐op‐
tica, Milan, Italy) and performed in accordance with manufacturer's 
protocols. Adipogenic differentiation was analysed using Oil red O 
staining as an indicator of intracellular lipid accumulation, chondro‐
genic differentiation was analysed using Alcian blue staining as an 
indicator of sulphated glucose‐aminoglycan‐rich extracellular matrix 
while osteogenic differentiation was analysed using von Kossa stain‐
ing as an indicator of calcified extracellular matrix.
2.9 | Reprogramming
Dermal fibroblasts from each anatomic site at passage 5 (n = 4) were 
reprogrammed using the Stemgent StemRNA‐NM Reprogramming 
Kit (Reprocell, Glasgow, UK), according to the manufacturer's pro‐
tocol. Briefly, on day 0, a total of 2.5 × 104 cells was seeded on 
each well of a 24‐well plate coated with hESC‐qualified Matrigel 
(Corning, Corning, NY) and cultured overnight at 37°C in 5% CO2, 
in Fibroblast Expansion Medium, prepared from Advanced‐DMEM 
(ThermoFisher Scientific), supplemented with 10% FBS (Sigma‐
Aldrich) and Glutamax Supplement (ThermoFisher Scientific). On day 
1, medium was changed to the iPSC cultivation medium NutriStem 
Medium (Reprocell) and transfection was performed after 6 hours 
using NM‐RNA Reprogramming Transfection Complex obtained by 
mixing the NM‐RNA Reprogramming Cocktail diluted in Opti‐MEM 
Reduced Serum Medium (reagent A) and Lipofectamine RNAiMAX 
Transfection Reagent, diluted in Opti‐MEM Reduced Serum Medium 
as well (reagent B) (all by ThermoFisher Scientific), according to the 
manufacturer's indication. Cells were then incubated for 15‐18 hours. 
Medium was, then, replaced and cells were allowed to recover for 
6 hours. After the recovery time, cells were transfected and incubated 
again. Overnight 15‐18 hour transfections followed by 6 hour recov‐
ery times were repeated for a total of four times, as recommended 
by manufacturer. Starting from day 5, cells were kept in culture in 
NutriStem Medium, changing the medium on a daily basis. The for‐
mation of colonies was monitored everyday and documented using a 
phase‐contrast microscope (Nikon) equipped with a stage incubator 
(Okolab). Three independent observers counted the emerging colo‐
nies at day 7 and 14 after the last transfection at the phase‐contrast 
microscope (Nikon), while the size of colonies was measured by the 
NIS Elements software (Nikon). Numbers were then averaged and ex‐
pressed as mean ± SE.
2.10 | Statistical analysis
Data were analysed by GraphPad Prism 5.0 (GraphPad Software, La 
Jolla, CA), using one‐way ANOVA test and Tukey's post test. A value 
of P ≤ 0.05 identified any statistically significant difference.
3  | RESULTS
3.1 | Fibroblast morphology in vitro
Outgrowth of fibroblasts occurred after 6‐7 days of culture (Figure 1A). 
Cells adhered to plastic culture dishes, where they spread and, in a 
time ranging from 14 to 21 days, they reached confluence (Figure 1B). 
Although most of the cells had spindle‐shaped morphology, star‐
shaped fibroblasts were observed in all culture dishes (Figure 1A).
3.2 | Proliferation and apoptotic indices, ability 
to migrate
To avoid any effect due to native environment, all primary fibroblasts 
were cultured under the same condition in vitro for five passages. 
Proliferation index, calculated as the percentage of cycling cells de‐
tected by the expression of ki67, was significantly lower (P ≤ 0.05) in 
fibroblasts from abdomen and thigh, than in fibroblasts from all other 
regions, being as low as 0.347 ± 0.094% in fibroblasts from abdomen, 
F I G U R E  1   Representative images 
of fibroblasts in vitro. A, outgrowth 
from the skin fragment (yellow star) of 
spindle‐shaped (white asterisks) and star‐
shaped (white arrowheads) fibroblasts in 
culture. B, fibroblasts in culture reached 
confluence in a time ranging between 14 
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and as high as 2.646 ± 0.303% in fibroblasts isolated from the neck 
skin (Figure 2A,B). Similarly, apoptotic index, calculated as the percent‐
age of apoptotic cells detected by TUNEL assay, varied among differ‐
ent fibroblast populations. In particular, rate of spontaneous apoptosis 
of dermal fibroblasts from both breast (3.792 ± 0.234%) and abdomen 
regions (2.089 ± 0.188%) was significantly higher (P ≤ 0.05) than the 
apoptotic rate of fibroblasts from the dermis of neck, arm and thigh 
regions (0.564 ± 0.090%, 1.059 ± 0,131% and 0.600 ± 0,148% respec‐
tively) (Figure 2 C,D). Moreover, fibroblasts from arm and thigh dermis 
migrated at higher speed (14.209 ± 3.769 and 10.499 ± 2.973 μm/h 
respectively) than fibroblasts from all other regions, whose speed of 
migration was comparable and ranging from 5.237 ± 1.749 μm/h, for 
fibroblasts from abdomen dermis, to 7.179 ± 2.449 μm/h, for fibro‐
blasts from neck dermis (Figure 2E‐G).
3.3 | Expression of mesenchymal and 
epithelial markers
All fibroblasts in culture were negative for epithelial and en‐
dothelial markers like E‐cadherin and Factor VIII (Figure 3). As for 
mesenchymal markers, variability related to anatomic site of origin 
occurred. Specifically, based upon vimentin and CD105 expres‐
sion, fibroblasts in culture were either mainly vimentin‐positive 
or mainly CD105‐positive (Figure 3). Interestingly, the propor‐
tion of such subpopulations of fibroblasts varied according to the 
anatomic site: fibroblasts isolated from neck and breast resulted 
mostly vimentin‐positive (Figure 3 A,D), while fibroblasts from 
the skin of abdomen and thigh consisted of mostly CD105‐posi‐
tive cells (Figure 3 J,M). No apparent difference among fibroblasts 
isolated from different regions emerged in the analysis of the ex‐
pression of CD90, instead (Figure 3). Additionally, gene expression 
analysis by qRT‐PCR confirmed the presence of gene transcripts 
for mesenchymal markers. CD90, ECM2, FN1 and WISP1 were 
expressed at similar levels among dermal fibroblasts isolated 
from different anatomic sites. Statistically significant differences 
(P ≤ 0.05) were observed in the expression of CD105 and CD146, 
instead. Specifically, higher expression of CD105 was observed 
in fibroblasts from breast, arm and abdomen, while significantly 
higher expression of CD146 resulted in fibroblasts from arm and 
abdomen (Figure 4).
F I G U R E  2   Quantification of proliferation index (A), apoptotic rate (C) and speed of migration (E) of fibroblasts from different anatomic 
sites, measured by expression of Ki67, TUNEL assay and scratch wound assay respectively. B, representative image of ki‐67‐positive cells 
in fibroblast culture (arrowheads); D: representative image of an apoptotic cell in fibroblast culture (arrowhead); (F) and (G) representative 
images of scratch wound assay of fibroblasts in culture at time 0 and after 12 h. Each value in graphs expresses the mean + SE of fibroblasts 
obtained from five different patients for each region (n = 5). Asterisks are indicators of the P value as follows: (A) extremely significant 
(***P ≤ 0.001) vs fibroblasts from abdomen and thigh; (C) **very significant (**P ≤ 0.01) vs fibroblasts from breast; (E) ***extremely significant 
(***P ≤ 0.001) vs fibroblasts from arm. (B) and (D) Scale bar length is 100 µm; (F) and (G) Scale bar length is 200 µm. At the upper left corner 
a scheme of anatomic sites of origin of fibroblasts is reported for quick reference
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3.4 | Mesenchymal differentiation and growth 
factor release
To test the ability to differentiate, human dermal fibroblasts were 
grown in culture medium supplemented with horse serum or with 
Transforming Growth Factor (TGF‐β) or with dexamethasone, 
ascorbic acid and β‐glycerophosphate. Even though fibroblasts 
isolated from all different regions clearly retained the ability to 
differentiate towards chondrocytes, osteoblasts and adipocytes, 
as shown by specific histochemical stainings (Figure 5), obvious 
F I G U R E  3   Representative images of immunocytochemistry for the in vitro expression of mesenchymal (A‐B, D‐E, G‐H, J‐K and M‐N) and 
epithelial (C, F, I, L and O) markers by dermal fibroblasts from neck (A‐C), breast (D‐F), arm (G‐I), abdomen (J‐L), and thigh (M‐O). Scale bar 
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F I G U R E  4   Real‐time PCR analysis of the expression of genes characteristic of mesenchymal cells. Each value expresses the mean of five 
samples for each region (n = 5) + SE. Asterisks are indicators of the P value as follows: CD105: significant (*P ≤ 0.05) vs fibroblasts from thigh 
and extremely significant (***P ≤ 0.001) vs fibroblasts from abdomen; significant (* P ≤ 0.05) vs fibroblasts from breast and thigh. WISP1, 
WNT1 inducible signaling pathway protein 1; FN1, Fibronectin 1; ECM2, Extracellular Matrix Protein 2.
F I G U R E  5   Following induction of 
adipogenic, chondrogenic and osteogenic 
differentiation, fibroblasts exhibited 
a dramatic change of phenotype as 
shown by representative images at 
phase‐contrast microscope (A, C, E). 
Specific stainings to identify intracellular 
lipid accumulation (Oil red O), sulfated 
glucose‐aminoglycan (Alcian blue) or 
calcium deposits (Von Kossa) confirmed 
the differentiation towards adipocytes 
(B), chondrocytes (D) and osteoblasts (F) 
respectively. Scale bar length is 200 µm 
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change of phenotype in culture in fibroblasts isolated from the 
skin of abdominal region was apparent as early as 6 days of cul‐
ture, while fibroblasts from all other regions required a time rang‐
ing from 10 to 15 days. The presence of specific growth factors 
capable of enhancing or impairing reprogramming was detected by 
protein array performed on culture medium obtained from fibro‐
blasts isolated from different anatomic sites. Statistically signifi‐
cant difference was observed in the release (P ≤ 0.05) of growth 
factors like Epidermal Growth Factor (EGF), Hepatocyte Growth 
Factor (HGF), Platelet‐Derived Growth Factor (PDGF), TGF‐β, 
Vascular Endothelial Growth Factor (VEGF) among fibroblasts of 
different origin (Figure 6). Specifically, dermal fibroblasts from ab‐
dominal skin released higher amounts of HGF, PDGF and VEGF, 
but significantly lower amounts of EGF and TGF‐β.
3.5 | Reprogramming of dermal fibroblasts
As a proof of concept we reprogrammed dermal fibroblasts using a 
ready‐to‐use kit and following the well‐established protocol supplied 
with the reagents.25‐27 The efficiency of reprogramming, in terms of 
time required for the formation of colonies and of number and size 
of colonies, varied enormously among fibroblasts and in accordance 
with the anatomic site of origin (Figure 7). Fibroblasts isolated from 
the neck, arm and thigh regions required 1 week after the last trans‐
fection for reprogramming, while fibroblasts isolated from the breast 
skin reprogrammed after 2 weeks and dermal fibroblasts from the 
abdomen region started arranging into small colonies after the very 
first transfection. As regards the number of colonies that formed 7 
and 14 days after transfection, no statistically significant differences 
emerged between fibroblasts isolated from the neck, arm or thigh 
skin after 7 days (14.17 ± 1.515, 15.29 ± 1.523 and 16.50 ± 0.964 
respectively) nor after 14 days (14.67 ± 2.404, 17.50 ± 2.102 and 
18.75 ± 0.75 respectively). Fibroblasts isolated from the breast skin 
formed colonies only after 14 days and their number was significantly 
lower (0.75 ± 0.491), while fibroblasts isolated from the abdominal 
skin formed a significantly higher number of colonies than fibro‐
blasts from all other regions, both after 7 and 14 days (48.58 ± 3.843 
and 43.00 ± 2.887 respectively). Finally, the size of colonies at day 
14 after transfection was also measured and the mean maximum 
diameter of colonies formed varied greatly, ranging from about 
0.3 mm to over 1 mm. Specifically, fibroblasts isolated from the 
abdominal skin formed the largest colonies (1141 ± 158.4 μm) that 
also resulted significantly larger than those formed by fibroblasts 
from breast (297.5 ± 31.26 μm), arm (472.0 ± 81.81 μm) and thigh 
(598.4 ± 46.28 μm) skin, while no statistically significant difference 
was observed in the size of colonies formed by fibroblasts from the 
skin of abdomen or neck (783.3 ± 139.5 μm).
4  | DISCUSSION
Induced pluripotent stem cells are clearly emerging as the most 
promising cell type in regenerative medicine, as they are autologous 
cells characterised by pluripotency comparable to that of ESCs. 
Nonetheless, several hurdles related to reproducibility and effi‐
ciency of reprogramming are yet to be overcome. Fibroblast was the 
first adult somatic cell to be successfully reprogrammed and thus 
far it is still the most used cell for reprogramming. Noteworthily, it 
has been previously demonstrated that fibroblast are not a homog‐
enous population28 and that cell origin and characteristics affect cell 
reprogramming.17 However, nor fibroblast features were evaluated 
nor the site of origin of fibroblasts was accurately selected before 
proceeding with the reprogramming. The present study aims at com‐
paring and analysing features of human dermal fibroblasts that may 
impact efficiency of reprogramming, to point out how important it is 
to accurately select the fibroblast population to improve reprogram‐
ming efficiency.
Dermal fibroblasts from five different anatomic sites (neck, 
breast, arm, abdomen and thigh) were isolated and cultured under 
the same culture conditions. All fibroblasts adhered and grew on 
plastic culture dishes, lacked expression of markers specific of 
other cell lineages and, in accordance with previous report of dif‐
ferent morphology in vitro,28 their morphology varied from elon‐
gated and spindle‐shaped to flattened and star‐shaped (Figure 1). 
Nevertheless, several other features, such as the expression of mes‐
enchymal markers, speed of migration, proliferation index, prompt‐
ness to acquire different phenotype and release of growth factors, 
varied greatly among dermal fibroblasts isolated from different 
anatomic sites. Based on expression of mesenchymal markers, fi‐
broblasts in culture consisted of either mostly vimentin‐positive 
or mostly CD105‐positive cells (Figure 3 and Figure 4). Such evi‐
dence was in agreement with fibroblast diverse ability to migrate, 
as vimentin is the mesenchymal intermediate filament essential to 
ensure migration.20,29 Indeed, mostly vimentin‐positive fibroblasts 
isolated from the arm skin migrated at considerable higher speed 
than all other fibroblast populations (Figure 2). Additionally, consis‐
tently with previous report of vimentin‐deficient fibroblasts exhibit‐
ing a slower rate of proliferation,21 fibroblasts isolated from the arm 
skin, along with fibroblasts from neck and breast regions, all mostly 
vimentin‐positive, proliferated at significantly higher rate than 
dermal fibroblasts from abdomen or thigh that showed a reduced 
expression of vimentin (Figure 2). Notably, accumulating evidence 
suggests that low proliferation rates of somatic cells enhance their 
reprogramming,30‐32 hence difference in proliferation rate of fibro‐
blasts isolated from different anatomic sites might indirectly sug‐
gest a diverse response of fibroblast populations to reprogramming. 
Despite the common expression of several transcripts of genes 
typically expressed in mesenchymal cells,33,34 there was a hetero‐
geneous expression of CD105 and CD146 when comparing dermal 
fibroblasts obtained from distinct anatomic sites, with fibroblasts 
isolated from abdomen skin that had a higher expression of all three 
markers. Our data are in disagreement with the previous proposal 
of using CD146 as a marker of mesenchymal stromal/stem cells 
(MSCs) that is based on the evidence that fibroblasts are CD146‐
negative.34,35 However, heterogeneity of MSCs as well as evidence 
that MSCs and fibroblasts cannot be unequivocally distinguished in 
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vitro have also been described.36 Indeed, apart from sharing most of 
the features and expression of markers of fibroblasts, MSCs, like fi‐
broblasts, exhibit striking variability among tissues of origin and do‐
nors that make even more difficult to define a subset of markers to 
clearly identify them,37‐39 to such an extent that MSCs isolated from 
adipose tissue have been described as a CD146‐negative cell pop‐
ulation.40,41 Interestingly though, expression of CD90, CD105 and 
CD146 by fibroblasts isolated from abdominal skin raise the thorny, 
and still unaddressed, question of whether fibroblasts and MSCs 
are not admittedly the same population.42,43 Based on our and other 
F I G U R E  6   Production and release of growth factors by dermal fibroblasts in vitro evaluated by growth factor protein array. A, 
Representative images of profiles of growth factors released by fibroblasts from different anatomic sites. B. Quantification of selected 
growth factors. Each value expresses the mean + SE. Culture medium from culture of fibroblasts obtained from three different patients 
for each site were assayed (n = 3). Asterisks are indicators of the P value as follows: significant (*P ≤ 0.05), very significant (**P ≤ 0.01), and 
extremely significant (***P ≤ 0.001) vs fibroblasts from abdomen (EGF, GM‐CSF, HGF, PDGF‐BB and VEGF) or fibroblasts from neck and 
abdomen (TGF‐β2). At the lower right corner layout of protein array and a scheme of anatomic sites of origin of fibroblasts are reported for 
quick reference. EGF, Epidermal Growth Factor; OD, optical density; HGF, Hepatocyte Growth Factor; VEGF, Vascular Endothelial Growth 
Factor; GM‐CSF, Granulocyte‐macrophage colony‐stimulating factor; PDGF‐BB, Platelet‐Derived Growth Factor‐BB
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authors' observations,33,34,41 it is reasonable to consider fibroblasts 
to be at least an MSC differentiation stage, and to infer that fibro‐
blast cell population comprises a variable number of MSCs, whose 
proportion is related to the anatomic site of origin and could cause 
the dermal fibroblasts from different anatomic sites to respond to 
reprogramming technology in different manner. This hypothesis is 
fully supported and strengthened by conflicting evidence of fibro‐
blast ability to differentiate towards chondrocytes, osteoblasts and 
adipocytes.41,44‐46 Although retained ability of dermal fibroblasts 
to differentiate into chondrocytes, osteoblasts and adipocytes 
emerged from our analysis (Figure 5), obvious difference emerged 
among fibroblasts from different regions. Indeed, change of pheno‐
type in fibroblasts isolated from the skin of abdominal region was 
apparent as early as 6 days of culture, while fibroblasts from all other 
regions required a time ranging from 10 to 15 days, confirming that 
the site of origin is responsible for functional diversity of dermal fi‐
broblast and that it is, realistically, related to a diverse proportion of 
MSCs in fibroblast cell culture, as MSCs are unquestionably capable 
F I G U R E  7   Reprogrammed human 
dermal fibroblast by mRNA direct 
delivery. On the left: representative 
images of colonies of induced pluripotent 
stem cells formed by fibroblasts from all 
five different anatomic sites at day 14 
after transfection. On the right: (A) and 
(B) quantification of colonies formed 
by fibroblasts from the five different 
anatomic regions at day 7 (A) and 14 (B) 
after transfection. Each value expresses 
the mean ± SE (n = 4) and the three 
asterisks are indicators of the P value 
as extremely significant (*** P ≤ 0.001) 
vs fibroblasts from the abdominal skin. 
C, measurement of the size of colonies, 
expressed as the maximum diameter in 
μm, formed by fibroblasts from the five 
different anatomic regions at day 14 
after transfection. Each value expresses 
the mean ± SE (n = 4) and asterisks are 
indicators of the P value as follows: 
significant (*P ≤ 0.05), very significant 
(**P ≤ 0.01) vs fibroblasts from the 
abdominal skin. At the bottom of the right 
side of the picture a scheme of anatomic 
sites of origin of fibroblasts is reported for 
quick reference
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of giving rise to all three mesenchymal cell lines. Interestingly, the 
presence of specific growth factors capable of enhancing or impair‐
ing reprogramming, 47‐50 as detected by protein array performed on 
fibroblasts isolated from different anatomic sites, provided addi‐
tional clue about diversity of fibroblasts and their diverse ability to 
respond to reprogramming technology. Notably, the release of the 
EGF, proved to be an enhancer of fibroblast proliferation51 and, as 
consequence, of impairing cell reprogramming,30 was significantly 
lower in culture of slow‐proliferating dermal fibroblast from ab‐
dominal skin and significantly higher in culture of fast‐proliferating 
fibroblasts from arm skin. On the contrary, the release of growth 
factors known to be inducers of cell reprogramming, like GM‐CSF,52 
HGF,53 PDGF 54,55 and VEGF 49 resulted significantly higher in der‐
mal fibroblasts from abdominal skin (Figure 6). Furthermore, as 
reprogramming of fibroblasts to iPSCs requires a mesenchymal to 
epithelial transition (MET),56 factors involved in the activation of 
MET or inhibition of the opposite process, the epithelial‐to‐mesen‐
chymal transition (EMT), have potential critical role in reprogram‐
ming. TGF‐β is a known inducer of EMT and its inhibition has been 
correlated with the enhancement of MET and reprogramming.50 
Intriguingly, the release of TGF‐β by fibroblasts from abdomen skin 
was significantly lower.
Evidence discussed thus far substantiates the hypothesis that 
human dermal fibroblasts derived from different sites have different 
features, including expression of mesenchymal markers, proliferation 
index, promptness to differentiate among mesenchymal cell lineages 
and production and release of growth factor. As all these features 
might remarkably affect the efficiency of reprogramming, we inferred 
that fibroblast topographic location might impact upon induction and 
efficiency of reprogramming. Hence, as a proof of concept we in‐
duced the reprogramming of dermal fibroblasts from all five anatomic 
sites following a well‐established mRNA‐based protocol. Remarkable 
differences in efficiency of reprogramming, in terms of ability to form 
colonies, emerged from reprogramming experiments. Indeed, fibro‐
blasts isolated from the skin of the abdominal region started repro‐
gramming as early as day 2, while fibroblasts from other regions took 
between 11 and 18 days to form colonies. Moreover, the number and 
size of colonies formed were dramatically and significantly higher 
in fibroblasts from the abdominal skin (Figure 7) that in fibroblasts 
from all other regions, providing evidence of higher efficiency of re‐
programming. Therefore, fibroblast reprogramming is more readily 
and efficiently accomplished from abdominal skin fibroblasts that are 
facilely and efficiently harvested by a skin punch biopsy that may be 
performed with a minor unaesthetic scar.
In conclusion, while offering novel perspective on the iPSC repro‐
gramming from dermal fibroblasts, our study also demonstrates that 
fibroblasts isolated from the skin of the abdomen represent the ideal 
dermal fibroblast for. As a result of their ESC‐like pluripotency, iPSCs 
are currently considered the most promising cell source for regen‐
erative medicine applications. Nonetheless, severe technical prob‐
lems related to both reprogramming technology and low efficiency 
of reprogramming still need to be addressed before clinical trans‐
lation. While the integration‐free methods like the reprogramming 
induced by direct delivery of modified mRNA employed in this study, 
with the possibility of applying the protocol in a complete xeno‐free 
culture environment, ensures safety for iPSC translation into clini‐
cal settings, the identification of a dermal fibroblast population that 
promptly responds to reprogramming procedure by quickly forming 
a number of large and well‐structured colonies has the tremendous 
potential of advancing iPSC technology and boost their use in clinical 
trials.
Additionally, while emphasizing fibroblast diversity and the im‐
pact of such diversity on cell reprogramming, our study also high‐
lights striking similarity between fibroblasts and MSCs that supports 
the attracting hypothesis that the most remarkable difference be‐
tween fibroblasts and MSCs is in the name.40‐43,57
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